Collagen decline is one of the most well-documented aspects of skin ageing. Here is what the research says about peptides studied for skin health and collagen pathways, and what therapeutic access looks like in Australia.
This article is for general educational purposes only and does not constitute medical advice. Therapeutic peptide use in Australia requires assessment and prescription from an AHPRA-registered medical practitioner. Peptide therapy is distinct from over-the-counter cosmetic products. Always consult a qualified doctor before making any decisions about your health.
Skin ageing is one of the most visible manifestations of biological ageing, and collagen decline is one of the most well-documented mechanisms behind it. Collagen, the primary structural protein of the skin, is produced at declining rates from the mid-20s onwards, with visible effects accumulating over subsequent decades. The search for approaches that can meaningfully support collagen synthesis and skin repair has been ongoing for decades, and several peptide compounds have attracted genuine research interest in this area.
This guide covers the biology of skin ageing, which peptide compounds have been most studied in skin and collagen contexts, what the evidence actually shows, and the important distinction between therapeutic peptide use and cosmetic over-the-counter products.
Skin ageing has both intrinsic and extrinsic components. Intrinsic ageing is driven by the biological processes that affect all tissues over time, including declining collagen production, reduced fibroblast activity, diminishing growth factor signalling, and accumulating cellular damage. Extrinsic ageing is driven by environmental factors, most significantly ultraviolet radiation exposure, which accelerates many of the same processes.
Collagen is the primary structural protein of the dermis, providing tensile strength, elasticity, and the architectural scaffold that gives skin its structure. Collagen production by fibroblasts declines progressively with age, while existing collagen is degraded by enzymes whose activity is accelerated by UV exposure and inflammation. The result is thinner, less elastic skin with reduced capacity to repair itself efficiently.
The research interest in peptides for skin health centres on compounds that may support fibroblast activity, collagen synthesis pathways, skin repair mechanisms, and the inflammatory processes that accelerate collagen degradation.
GHK-Cu is the most extensively researched peptide in skin and collagen contexts. A naturally occurring copper peptide found in human plasma at concentrations that decline with age, research has examined its interaction with fibroblast activity, collagen synthesis, wound healing, skin repair, and more recently gene expression relevant to skin biology. It appears in both cosmetic skincare formulations and therapeutic contexts, though the concentrations and delivery methods differ significantly between these two uses.
BPC-157 is primarily studied for musculoskeletal and gastrointestinal tissue repair, but the repair mechanisms it interacts with are relevant to skin as well. Research has examined its interaction with growth factor signalling and the tissue repair environment in various tissue types including skin. Its relevance to skin health is through its broader tissue repair mechanisms rather than skin-specific pathways.
Growth hormone plays a role in skin thickness, collagen synthesis, and skin repair capacity. Growth hormone levels decline with age, contributing to age-related skin changes alongside collagen decline. Growth hormone pathway peptides are studied for their downstream effects on skin biology as one component of their broader influence on tissue repair and body composition processes.
Chronic inflammation, sometimes called inflammaging, accelerates collagen degradation and skin ageing. Thymosin Alpha-1, studied for its immune-modulating properties, is relevant to skin health indirectly through its interaction with inflammatory pathways. Reducing chronic low-grade inflammation is one approach researchers have studied in the context of supporting healthier skin ageing.
This distinction matters significantly for understanding what the research shows and what therapeutic access actually means. GHK-Cu, the most studied skin-relevant peptide compound, appears in over-the-counter cosmetic skincare products in many countries, including Australia. These products are regulated as cosmetics, not medicines, and the concentrations and delivery methods are different from therapeutic use.
When GHK-Cu or other peptide compounds are accessed through a licensed compounding pharmacy via a doctor's prescription, the concentration, delivery form, and administration route are determined by a prescribing doctor based on clinical assessment rather than cosmetic product marketing. This is a meaningfully different context from applying a skincare cream, and the research most relevant to therapeutic use involves different parameters than the research used to support cosmetic product claims.
Why therapeutic peptides for skin differ from skincare products: The skin barrier limits how much of any topically applied compound can penetrate to the dermis where collagen is produced. Injectable or other systemic delivery methods used in therapeutic contexts bypass this barrier limitation. Research examining injectable GHK-Cu, for example, is examining a different set of potential effects to research on topical GHK-Cu in cosmetic concentrations. A prescribing doctor determines which approach and delivery method is appropriate for any individual.
GHK-Cu has one of the more developed research bases for skin-relevant applications of any peptide compound. Research has examined its interaction with fibroblast activity, collagen and elastin synthesis pathways, wound healing processes, and gene expression relevant to skin biology. Some of this research is in human contexts, which distinguishes it from compounds whose skin-relevant evidence is primarily preclinical.
For other compounds like BPC-157 and growth hormone pathway peptides, the skin health applications are indirect. These compounds are not primarily studied for skin health, but their interaction with tissue repair mechanisms and growth hormone pathways has downstream relevance to skin biology as one of many tissues that depend on these processes. Whether they are appropriate as part of a skin health-focused protocol depends on the individual's full health picture and the prescribing doctor's clinical assessment.
Skin health is sometimes addressed as a primary goal of a peptide protocol and sometimes as a secondary benefit of a protocol focused on broader longevity or tissue repair goals. The approach that makes most sense for any individual depends on their specific health picture, what they are trying to address, and the prescribing doctor's assessment of what compounds are most relevant to their situation.
The assessment process starts for free. A prescribing doctor reviews your health history, skin health concerns, and goals, and determines what is clinically appropriate for your specific situation. There is no cost until you choose to proceed.
Start with a free assessment. A doctor reviews your health picture and builds a protocol around your specific situation if one is appropriate. No cost until you choose to proceed.